Lilly recently began marketing their U200 Humalog Kwik-Pen. This pen contains rapid-acting lispro insulin that is twice as potent as ordinary lispro.
The recent online explosion of comments regarding the poorly dramatized experience of a woman with type 1 diabetes in the BBC’s season finale of The Syndicate shows just how uneducated people without diabetes are – even if they are a writer for a big name show.
We all have many hats that we wear in our lives - parent, partner, colleague, community member etc. For me, two of my most important roles are that of being a mother and a Diabetes Educator. The fact that my son has type 1 diabetes means that these roles intersect and overlap on a regular basis.
It is with great pleasure that we have a special opportunity to post Dr. Steve Edelman & Dr. Jeremy Pettus's ADA recap from the recent ADA Scientific Sessions in Boston.
Vibe is the first and only insulin pump to integrate all the features of the Dexcom G4 display module into the pump itself. That’s right! No need to tote around a separate CGM display. I was given a 2-week trial/demo of the Vibe by Animas in mid-December, and promptly wore it on a one-week family cruise vacation and through the holidays. I must say, having the Dexcom CGM data right on the pump gave me a nice sense of autonomy.
When I hear the word “bionic,” I can’t help but have the opening theme of the 70s TV show “The Six Million Dollar Man” pop into my head. Then I come back to the 21st century, and ponder the exciting innovations of the bionic pancreas project.
On June 27, 2014, the FDA announced the long-awaited approval of AFREZZA, an insulin delivered by inhalation, for adults with diabetes requiring meal-time insulin.
After nearly 30 years of living with type-1 diabetes and 20 years teaching patients how to better manage it, a few things have become apparent.
My own personal liraglutide (Victoza) experiment continues. Victoza is an injectable GLP-1 medication manufactured by Novo Nordisk. It is commonly used in treatment of type-2 diabetes, but its effects seem to offer benefits for those with type-1 as well. A small study at U of Buffalo (NY) showed that adding liraglutide to an intensive insulin program can reduce appetite, insulin requirements and glucose variability. I've seen the reduction in appetite personally, and hence a reduction in bolus requirements. I've also seen a small reduction in basal insulin requirement due, presumably, to the inhibition of glucagon secretion by liraglutide. My one concern is that I've had to keep increasing my dose of liraglutide in order to maintain the appetite suppression. I started out at 0.6 mcg and am now up to about 1.5 mcg (the maximum dose is 1.8). Why the constant buildup of "tolerance" to the medication? Beats me. But I'll keep working with it to learn as much as I can and, hopefully, improve my own BG control along the way.